Pfizer says that it is "reviewing strategic alternatives" for its Capsugel business and that divestiture is an option. Capsugel manufactures capsules, including Vcaps hypromellose capsules for inhalation applications, and the Xcelodose powder dispensing system. 2009 revenue for Capsugel was approximately $740 million. Pfizer expects to make a decision early in 2011. Read the company’s press release.
Pfizer considers divesting Capsugel
published on
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
December 9-December 11: DDL 2026, Edinburgh, Scotland
April 27-30: RDD Europe 2027, Antibes, France
May 12-13: USP Joint Workshop: Quality and Product Performance Testing of Orally Inhaled and Nasal Drug Products, Rockville, MD, USA
June 30: RespireX 2027, Boston, MA, USA
